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AbstrACt
Introduction Richter’s transformation (RT) refers to the 
development of an aggressive lymphoma in patients 
with chronic lymphocytic leukaemia (CLL) or small 
lymphocytic lymphoma. Studies have shown that 2–10% 
of patients with CLL develop RT including diffuse large 
B-cell lymphoma (DLBCL) and less common Hodgkin 
lymphoma (HL). This study aims to assess the risk factors 
for RT of CLL in a nationwide cohort. Additionally, we want 
to examine prognostic factors in patients with RT. These 
findings may guide management of treated as well as 
untreated patients with CLL in the risk of RT.
Methods Clinical data for patients diagnosed with CLL 
between 2008 and 2016 will be retrieved from the Danish 
National CLL registry (DCLLR). Using the Danish unique 
person identification number, clinical data will be merged 
with histologically verified DLBCL and/or HL diagnoses 
retrieved from the Danish National Pathology Data Bank. 
This will ensure complete follow-up for all patients. The 
DCLLR includes data from more than 4000 patients 
with CLL ensuring a median follow-up of 3 years. With 
the reported incidences (2-10%) of RT, we expect to 
identify 80–200 CLL patients with RT enabling analysis of 
overall survival following RT. From time of CLL diagnosis, 
estimates of cumulative incidence of RT will be calculated 
using the Aalen-Johansen estimator. From time of RT 
diagnosis, survival analysis will be performed by Kaplan-
Meier method. Cox proportional hazards models will be 
used for multivariable survival analysis.
Ethics and dissemination Approvals for data collection 
and analysis was obtained from the Danish Data Protection 
Agency and the Danish Health Authorities. All data will 
be managed confidentially according to guidelines and 
legislation. The dissemination will include a publication of 
scientific papers and/or presentations of the study findings 
at international conferences.
IntroduCtIon
Chronic lymphocytic leukaemia (CLL) 
is the most common form of leukaemia 
in adults.1 Approximately 400 people are 
diagnosed with CLL in Denmark each year 
with increasing incidence.2 CLL is character-
ised by a heterogeneous disease course where 
some patients require initial treatment, while 
about 40% remain untreated.2 Patients with 
CLL can be stratified into four different risk 
groups: Low, intermediate, high or very high 
risk based on the CLL international prog-
nostic index.2 Despite an improved prognosis 
following the introduction of chemo-im-
munotherapy and targeted therapy,1 Rich-
ter’s transformation (RT) still affects about 
2%–10% of patients with CLL.3–5
RT, defined as the transformation of CLL 
or small lymphocytic lymphoma into an 
aggressive lymphoma (diffuse large B-cell 
lymphoma (DLBCL) or Hodgkin’s lymphoma 
(HL)) is one of the most severe complications 
associated with CLL.3 4 6 7 The median time 
from the CLL diagnosis until RT occurs to lie 
in the range of 2–4 years, but some patients 
are diagnosed with RT concomitant with 
CLL.3 7 8 Rarely, some patients are diagnosed 
with RT at the time of CLL diagnosis.1 The 
strengths and Limitations
 ► Largest study to date on Richter’s transformation 
(RT) including a nationwide cohort of approximately 
4000 CLL patients with an expected prevalence of 
80–200 RT patients.
 ► Multivariable models of risk factors will be 
performed.
 ► Predefined analyses according to published protocol.
 ► Methodological challenges to conduct research in 
this area.
 ► Confounding effects of socioeconomic status, eth-
nical, dietary and geographical differences on RT 
development will not be adjusted for.
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clinical course of RT is aggressive with a reported median 
survival of 1–2 years.9–11
Risk factors for transformation may differ from risk 
factors for CLL progression.10 Therefore, RT may not 
necessarily be predicted from studies of CLL. Previous 
studies have identified that clinical (Binet stage B/C, 
performance status, lymphadenopathy), biochemical 
(lactate dehydrogenase elevation), biological (unmu-
tated IGHV, expression of CD38 and ZAP70) and cyto-
genetic (del(13q) absence), (tri12), del(11q) and 
del(17 p) factors are associated with an increased risk of 
RT (table 1).7 8 10 12
Recently, studies have identified distinct genetic mech-
anisms by which CLL transforms into an aggressive 
lymphoma. Disruption of TP53, NOTCH1 and CDKN2A, 
as well as c-MYC activation were associated with develop-
ment of RT.3 7
It is still controversial whether CLL therapy (purine-nu-
cleoside analogue and/or targeted therapy) affects the risk 
of RT.8 11 Nevertheless, early transformation on targeted 
therapy is a concern for physicians as well as patients with 
aggressive CLL.13 As these patients may possibly benefit 
from alternative therapeutic strategies including inten-
sive chemoimmunotherapy and allogeneic stem cell 
Table 1 Summary of the included possible risk factors
Demographical Gender (male)
Age (>65 years)
Clinical Advanced binet stage (B/C)
CLL-IPI score (>1)
B-symptoms (unintentional weight loss, extensive tiredness, fever (>38.0℃), night sweats)
Lymphadenopathy (size (diagonal measure, cm), number of lymph nodes and number of nodal areas)
Splenomegaly (>12 cm)
ECOG-PS (>1) 
Smoking status (yes/no)
Comorbidities (CIRS and CCI)
Genetic/Biological Del(13q) absence, normal FISH
Tri12
Del(11q)
Del(17 p)
TP53 mutation status
CDKN2A and NOTCH1 mutation status
Unmutated IGHV status (≥98 germline identity)
CD38, CD49d, ZAP-70 positivity (Population > 30% positive)
Ki-76, C-MYC, PAX-5, BcL-2, Bcl-6, CD79-a, MUM-1 positivity on pathology samples following RT
DLBCL subtype (GCB or ABC)
Biochemical21 Haemoglobin (<10 g/dl)
Platelet count (<100×109/L)
Peripheral blood leucocytes (>8,8 109/ L)
Peripheral blood lymphocytes (5×109/ L)
Peripheral blood neutrophils (<2.25×109/L)
β−2-microglobulin elevation (>4 mg/L ng/mL)
Lactate dehydrogenase elevation (>205 U/L)
Abnormal levels of immunoglobulins (IgM, IgG, IgA)
Treatment-related CLL-treatment regimens
Chemoimmunotherapy (purine-nucleoside analogue and/or alkylating agents plus/minus monoclonal 
antibody therapy and/or kinase inhibitor therapy)
Stem cell transplantation
Radiation therapy
RT-treatment regimens
Chemoimmunotherapy (purine-nucleoside analogue and/or alkylating agents plus/minus monoclonal 
antibody therapy and/or kinase inhibitor therapy)
Stem cell transplantation
Radiation therapy
ABC, activated B-cell-like; CCI, Charlson Comorbidity Scoring System; CDKN2A, cyclin-dependednt kinase Inhibitor 2A; CD38, cluster of 
differentiation 38; CD79-a, cluster of differentiation 79; CIRS, Cumulative Illness Rating Scale; CLL, chronic lymphocytic leukemia; CLL-IPI, 
International Prognostic Index of CLL; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group Performance 
Status (ECOG-PS); FISH, Fluorescende In Situ Hybridization; GCB, Germinal center B-cell-like; MUM-1, multiple myeloma oncogene 1 
NOTCH1, neurogenic locus notch homolog protein 1; PAX-5, paired box protein 5; RT, Richter’s Transformation; TP53, tumor protein p53; 
ZAP-70, zeta-chain-associated protein kinase 70. 
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transplantation, it is important to identify patients with 
increased risk of RT before initiating CLL therapy.12 14
research questions
1. What is the incidence of Richter’s transformation (RT) 
in a nationwide cohort?
2. Are we able to confirm risk factors already identified in 
previous studies?
3. Can we identify novel risk factors for development of 
RT?
4. Does treatment of chronic lymphocytic leukaemia af-
fect development of RT?
5. How do these risk factors impact overall survival?
MEthods And AnALysIs
study design
The study protocol for identification of patients with 
RT, data collections and data analyses are summarised in 
figure 1.
Patient identification
All patients in the Danish CLL Registry (DCLLR) 
between 2008 and 2016 are included, since it is manda-
tory for all physicians to report CLL patients in this 
registry. The registry includes patients  diagnosed with 
CLL according to the International Workshop on CLL 
(IWCLL) criteria, a Danish address and a valid personal 
identification number. Therefore, this registry comprises 
data on all patients diagnosed in Denmark, including 
date of birth, gender, date of death, treatment regimens 
and risk factors.7 13
Patients identified from DCLLR with a concomitant 
biopsy proven diagnosis of DLBCL and/or HL from 
the Danish National Pathology Data Bank (Patobank) is 
considered to have RT and will be included in this study. 
Patobank is a national histopathology and cytopathology 
register founded in 1978 and is now nationwide.15 System-
atized Nomenclature of Human Medicine codes included 
in this study are summarised in box 1.
A strategy for collecting information on RT patients 
will consist of a double-controlled reading. Once the 
initial reading of a patient chart is completed, a second 
researcher will verify the collected data.
Patients and public involvement
Involvement of all Danish CLL patients will be ensured 
through nationwide registries. Since data will be collected 
in a retrospective manner, the CLL patients are unable 
to participate and engage directly in this current study. 
Our research results concerning risk factors for RT 
will broaden the understanding of RT among CLL 
patients. This may potentially cause national and local 
health changes, that directly responds to the concerns 
and real-life experiences of CLL patients. By gathering 
data, evidence and knowledge in this study, direct influ-
ence on the understanding of RT in CLL may modify 
national guidelines. New insights into the barriers of RT 
may develop approaches that researchers can use when 
handling additional aspects of CLL patients in risk of RT.
statistical analysis plan
Patients will be followed from time of CLL diagnosis until 
death or end of follow-up, whichever comes first.
The statistical analysis in this study will be based on 
baseline characteristics where we will examine three time 
points.
1. In the time from CLL diagnosis to diagnosis of RT, risk 
factors will be investigated to determine their impact 
on RT (table 1).
Figure 1 Flowchart of the study design. CLL, chronic 
lymphocytic leukemia; DCLLR, Danish National Chronic 
Lymphocytic Leukemia Registry; RT, Richter’s transformation; 
SLL, small lymphocytic lymphoma; SNOMED, Systematized 
Nomenclature of Human Medicine. 
box 1 systematized nomenclature of human Medicine 
(snoMEd) codes
M96503 Hodgkin’s lymphoma.
M96512 Hodgkin’s lymphoma, classical type, in incomplete remission.
M96513 Hodgkin’s lymphoma, classical type.
M96518 Hodgkin’s lymphoma, classical type, in remission.
M96523 Hodgkin’s lymphoma, MC type.
M96533 Hodgkin’s lymphoma, LD type.
M96593 Hodgkin’s lymphoma, nodular lymphocyte predominant.
M96633 Hodgkin’s lymphoma, NS type.
M96793 Mediastinal large cell B-cell lymphoma.
M96803 Diffuse large cell B-cell lymphoma.
M96823 Diffuse large cell B-cell lymphoma, immunoblastic variant.
M96833 Diffuse large cell B-cell lymphoma, T-cell/histiocytic variant.
M96853 Intravascular large cell B-cell lymphoma.
ÆYYY0X Transformation. 
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2. From time of initiating treatment to time of RT diag-
nosis, we will investigate the impact of CLL treatment 
on the risk of development of RT.
3. From RT diagnosis to death, we will measure the influ-
ence of the risk factors on the overall prognosis of RT.
Descriptive analysis of all possible risk factors (table 1) 
will be performed. For continuous variables, the mean, 
SD or median and IQR values will be reported according 
to distribution. The categorical data will be presented 
with frequency tables (n, %).
The Aalen-Johansen estimator will be used for cumula-
tive incidence. The Kaplan-Meier method will be used for 
overall survival. Log-rank and Gray’s test will be used to 
test differences between groups.
CLL patients without RT obtained from the DCLLR will 
represent our control group. The data from this control 
group will be compared with data from RTpatients 
collected from Patobank.
Cox models for multivariable analysis will be performed 
with backward elimination. Statistical significance will be 
defined as a p value of less than 0.05. All data manipula-
tion, visualisation and statistical analysis will be performed 
with R.16
dIsCussIon
RT is one of the most severe complications of CLL. The 
previously published retrospective studies have identified 
clinical, biochemical, biological as well as genetic charac-
teristics in CLL patients to be important risk factors for 
RT.7 8 10 11
Our study will be the first nationwide study to investi-
gate the incidence of RT and analyse the impact of risk 
factors in multivariable analyses. Moreover, we will be 
able to assess if different treatment regimens are asso-
ciated with higher risk of RT, thus answering important 
questions in our understanding of RT.
strengths
The key strength of our study is the nationwide setup, 
with a consecutive cohort of more than 4000 CLL patients 
and a predefined analysis plan and protocol. The Danish 
unique identification number enables us to merge 
registry data to ensure a complete follow-up in an unse-
lected real world CLL population.17 18 We expect to find a 
total of 80–200 RT patients, enabling us to assess multiple 
factors for both risk of RT and survival following RT. In 
contrast, single centre studies often represent data with 
a risk of selection-bias towards a higher socioeconomic 
status, hence a healthier patient cohort.19 This cohort will 
ensure a high coverage of all patients diagnosed with CLL 
within a nine-year period,2 due to the cross validation of 
DCLLR with other registries.
Through a manual, double-controlled assessment of 
medical records, we will assess multiple risk factors in 
association to outcomes. The data assembly from medical 
records will ensure information on both patient-specific 
and disease-specific variables, as well as information 
on treatment variables and response to treatment. 
The crossed reading of the medical records ensures a 
complete data collection, minimising the amount of 
missing information.
With this approach, our outcomes are expected to add 
further evidence to existing knowledge on potential risk 
factors identified so far.
Investigation of the clonal relationship is of high clin-
ical importance. Recent studies have shown that the 
clonal relationship between DLBCL and the underlying 
CLL has critical prognostic implications in RT.20 However, 
the question concerning clonal relationship between 
DLBCL cells and the pre-existing or concomitant CLL 
remains unanswered. In this respect, a possible follow-up 
study using tissue samples, will determine the prognostic 
impact of clonal status in RT patients.
Studies examining clonality and genetic associations 
to RT are therefore needed for novel treatment targets 
in patient at high risk of RT. We suggest implementing 
a high degree of screening and careful, long-term moni-
toring programmes to identify CLL patients harbouring 
relevant risk factors. High risk of RT may influence the 
patient counselling, making patients more aware of 
systemic symptoms which facilitates an early diagnosis of 
RT. By promptly detecting RT in these patients, we expect 
a more favourable prognosis.
Limitations
To address research questions in rare complications to 
rare cancers, prospective studies are not always feasible. 
Thus, knowledge concerning risk factors predicting RT 
in CLL patients is limited. Retrospective studies are there-
fore necessary to determine the risk factors. These studies 
are often susceptible to methodological bias and chance 
findings, which is also a major limitation in our study.
Even though DCLLR is highly validated, we cannot fully 
exclude selection bias in our study.17 We must consider 
that some departments have a more thorough registra-
tion than others, even though the cross validation with 
other health registries aim to minimise any selection bias.
Due to limited information on socioeconomic status as 
well as ethnical, dietary patterns and geographical differ-
ences, the impact of such on RT cannot be addressed in 
this study.
Despite the limitations, this protocol describes an 
approach to enable further testing of evidence concerning 
risk factors and outcomes of RT. We aim to establish clini-
cally significant risk factors that can potentially guide the 
management of patients with CLL.
The results from this study may be used to create a risk 
model to stratify patients with RT into three prognostic 
groups; high, intermediate and low risk. Hereby, we can 
stratify patients with potential implications on medical 
practices. These results are expected to add further on 
potential risk factors identified so far.
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